- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Eric Donnenfeld Talks Xdemvy Approval, Effect on Patients
Eric Donnenfeld, MD, from Ophthalmic Consultants of Long Island, discusses the importance of the Xdemvy FDA approval in treating patients with Demodex blepharitis.
Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island, discussed how treatment for Demodex blepharitis and Demodex mites will change with the recent approval of Xdemvy.
Transcript
How will the approval of Xdemvy change the way that Demodex mites and Demodex blepharitis are treated?
So it's very exciting that Xdemvy, the generic name is lotilaner, was approved by the FDA in late July. This is the first FDA-approved medication for treating Demodex blepharitis.
Demodex blepharitis is one of the most common diseases that we face on an everyday basis in our clinics and is responsible for ocular redness, irritation, many times with itching, and can participate in development of meibomian gland dysfunction. So, for the first time, we have a drug that can treat 1 of the most common diseases we see on a regular basis that impacts the ocular surface, and I feel that Xdemvy will have a profound effect on improving patient's ocular surface as well as improving their eyes and making them appear less red.
How are patients responding now that this treatment is available?
Xdemvy was recently approved, and it's been really a home run with a lot of interest in using Xdemvy for treating Demodex blepharitis. And this just makes sense, because we don't really have treatments that are available for this common disease. Early data shows that patients are responding to this treatment with Xdemvy, and I, personally, have had several patients who've had chronic, recrudescent inflammation, redness, and uncomfortableness in their lids who have responded beautifully to the use of this new medication.
So, it's wonderful that for the first time we have a drug that can actually treat one of the most common diseases we see in our clinic on a daily basis.
FDA Approves Nirogacestat for Treatment of Desmoid Tumors
November 28th 2023Desmoid tumors are noncancerous growths that appear in connective tissue, most often on the arms, legs, and abdomen. Aggressive tumors must be treated with surgery, radiation, or chemotherapy to keep them from growing into nearby organs, which can make them life threatening. They can cause pain and disfigurement, and they can reduce functioning and quality of life.
Read More
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
The FDA has approved pembrolizumab (Keytruda) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
